Navigation Links
INTUNIV demonstrated symptom reduction on oppositional subscale Conners' ADHD rating scale
Date:10/30/2009

HONOLULU - October 29, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV (guanfacine) Extended Release Tablets, at a major psychiatric medical meeting today. The primary objective of this study was to assess the change from baseline on the oppositional subscale of the Conners' Parent Rating Scale-Revised: Long Form (CPRS-R:L) in patients ages 6 to 12 with a primary diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) with the presence of oppositional symptoms at baseline. INTUNIV met the primary objective demonstrating significant efficacy in reducing symptoms as measured by the oppositional subscale. Some of the symptoms measured by this scale include deliberately doing things that annoy others, refusing to comply with adults' requests, and being touchy or easily annoyed by others.

According to the Centers for Disease Control and Prevention (CDC), approximately 7.8 percent of all US school-aged children have been diagnosed with ADHD at some point in their lives. ADHD is a complex neurobehavioral disorder, which includes symptoms and behaviors such as inattentiveness, running around or climbing excessively, and being excitable or impulsive, many of which can be disruptive.

"The disruptive nature of ADHD can impact social and academic settings for those patients diagnosed with the disorder," said F. Randy Sallee, MD, PhD, Professor of Psychiatry at the University of Cincinnati and Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio. "This study showed that INTUNIV is an effective option for treating a range of ADHD symptoms."

INTUNIV, a once-daily formulation of guanfacine, was approved by the US Food and Drug Administration (FDA) on September 2, 2009 as the first selective alpha-2A agonist for the treatment of ADHD. Although the mechanism of action is not known, guanfacine, the active ingredient in INTUNIV, is thought to sel
'/>"/>

Contact: Matt Cabrey
mcabrey@shire.com
484-595-8248
Porter Novelli
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Shires INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms
2. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
3. Vyvanse Capsules CII administration through 2 routes demonstrated similar pharmacokinetic profile
4. Comparative Effectiveness Research Study in Mayo Clinic Proceedings Demonstrated Asthma Patients Had Better Overall Results with Oral Controllers than Inhaled Products
5. New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes
6. Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer
7. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
8. New AMITIZA 8 mcg phase III studies demonstrated overall symptom improvement in adult women
9. How embryonic stem cells develop into tissue-specific cells demonstrated
10. ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
11. Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... death from "rat-bite fever" of a 10-year-old San Diego boy ... a report from the U.S. Centers for Disease Control and ... illness that should be considered in persons with rash, fever ... is reported," said a team led by Dr. Jessica Adam ... in the report occurred in August of 2013. Adam,s ...
(Date:12/19/2014)... Randy Dotinga ... News) -- Common painkillers, including ibuprofen, might slightly reduce ... researchers say. Use of ibuprofen (Advil, Motrin) and ... cell skin cancer by 15 percent, the researchers concluded ... is usually caused by sun exposure. ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Prostaglandin analogue ... -- significantly reduce the risk of vision loss in ... British researchers led by David Garway-Heath, of the ... London, tracked outcomes for more than 500 people newly ... of the disease and one of the leading causes ...
(Date:12/17/2014)... 2014 While countless companies tempt patients to ... the potential dangers of their purchase. Not only is the ... qualified doctor, but patients who buy hCG online are typically ... is actually no real hCG present. Illegal internet hCG is ... no safety standards and may contain unknown fillers that can ...
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
Breaking Medicine News(10 mins):Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3
... DDS, and her staff will be racing to save lives ... of Baltimore,s 2009 Susan G. Komen Race for the Cure. ... Team Chincheck has raised more than $4,700 for breast cancer ... affected by breast cancer and witnessing their strength and courage ...
... some parents may be lukewarm to the H1N1 vaccination, ... of Southern California,s largest integrated, comprehensive healthcare organizations, reports ... access to the vaccine. In response, Lakeside Community Healthcare ... patients direct access to the information they need to ...
... ... tourism industry, announced the addition of certain providers of Sistemas Medicos Nacionales, S.A. de C.V. ... ... , a global health care company in the emerging medical tourism industry, announced the addition ...
... Oct. 14 Usinas,Siderurgicas de Minas Gerais S.A. - USIMINAS (OTC: USNZY) (BOVESPA: USIM3,USIM5, USIM6) ... Third Quarter 2009 Results Conference Call. Results will be, ... after Bovespa,s trading session., ... third quarter 2009 results, ...
... Peter Sheldon, Vice President of Operations for Coverall Health-Based ... will be a featured speaker at the Professional Retail ... on October 14-15 at The Fairmont Hotel in Dallas, ... Best in Your Business with Best Practices." Sheldon will ...
... Terumo ... the latest developments in its advanced DuraHeart™ Left-Ventricular Assist System at the 23rd Annual ... , ... Mich. (PRWEB) -- Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, today ...
Cached Medicine News:Health News:Team Chincheck Goes Miles for Smiles 2Health News:Leading Southern California Physicians Report Patient Fears About Complexities of Flu Season 2Health News:SIMNSA is added to the Satori Global Network™ in Mexico to Offer U.S. Employers Cross Border Health Benefit Options 2Health News:Webcast Alert: Usinas Siderurgicas de Minas Gerais S.A. - USIMINAS Announces Third Quarter 2009 Results Webcast 2Health News:Coverall Executive Peter Sheldon To Be Featured Speaker at PRSM Mid-Year Conference 2Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 2Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 3
(Date:12/17/2014)...  Northstar Global Business Services, Inc. (OTCPink:MDIN) today ... made their final decision and has determined to ... effective December 15, 2014, and has resumed accepting ... book entry transfer services. All deposit restrictions have been ... fully "DTC Eligible", and has resumed electronic trading ...
(Date:12/17/2014)... -- , The new Dompé ... information concerning the biopharmaceutical Group,s national and international clinical research ... the recently launched institutional website that is receiving accolades from ... a new chapter in the fascinating story of Drug Discovery ... panoramic hub on the world of clinical research, ranging from ...
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... FRANKLIN LAKES, N.J., Oct. 16 Medco Health Solutions, ... of the Medco Foundation -- a non-profit organization to ... public about health, wellness and medicine safety issues; providing ... with access to medicine and information about medicine; and ...
... 16 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) will ... at 1:30 p.m. eastern time on Oct. 19, 2009. , ... management presentation which will follow. During that presentation, management will ... The webcast can be accessed via a link on the ...
Cached Medicine Technology:The Medco Foundation Joins With the Entertainment Industry Foundation to 'Give Health a Hand' to Communities in Need 2The Medco Foundation Joins With the Entertainment Industry Foundation to 'Give Health a Hand' to Communities in Need 3
... Plus, the fourth in the Clarity ... oximeter/ECG/Respiration Monitor, with 3 or 5 ... with SAC (Serial Autocorrelation) technology, and ... display provides two user configurable traces. ...
... BCI 3180 Pulse Oximeter is a cost-effective, ... 2 pulse rate and pulse strength ... This AC or battery powered unit ... alarm limits and up to 30 hours ...
... intraocular lens is a second-generation refractive multifocal ... greater independence from glasses than monofocal IOLs. ... range of vision that monfocals cannot match. ... distributes light over five optic zones so ...
... exams you want: ,Four probe choices, single degree ... path probe in the industry, gives you the ... need to. From full sulcus-to-sulcus measurements to ... provides the clarity of images and resolution you ...
Medicine Products: